Catalyst
Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in non-small cell lung cancer set to begin in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 13, 2017
Occurred Source:
http://files.shareholder.com/downloads/REGN/5250934809x0x966618/7AEDA08B-6093-48ED-8483-744E18D1AB5D/REGN_News_2017_12_13_General_Releases.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Non-small Cell Lung Cancer, Pd-1, Phase 2
